PercuSurge pioneered a new market segment in interventional cardiology products with a series of balloon catheters designed to trap and remove the potentially harmful debris that breaks loose during balloon angioplasty and stent placement procedures.
Latest PercuSurge News
Jul 21, 2017
In a move that will further enhance its interventional vascular product offerings, Medtronic Inc. (Minneapolis) today announced that it will acquire Sunnyvale, CA-based PercuSurge Inc. The merger agreement calls for an exchange of stock valued at approximately $225 million. Further financial details were not disclosed. PercuSurge will join the Medtronic Vascular organization, which is headquartered in Santa Rosa, CA. "We are excited to be joined by this innovative company, whose embolic protection device is the 'best in class' solution for reducing clinical complications associated with embolic debris released during interventional procedures," said Andy Rasdal, president of Medtronic Vascular. "We believe that our technology and excellent clinical results, combined with Medtronic AVE's worldwide operational and field infrastructure will result in an extremely rapid adoption of our technology to treat the nearly 200,000 diseased saphenous vein bypass grafts that could be treated each year," said Peter Rule, president, CEO and chairman of PercuSurge. The PercuSurge GuardWire Plus Temporary Occlusion and Aspiration system is designed to allow cardiologists and other interventional specialists to capture embolic debris that might otherwise block downstream vessels and branches during interventional procedures and damage the heart. It consists of a balloon-tipped guidewire, which is inflated briefly to occlude blood flow and capture any material dislodged from the wall of the vessel during placement of a stent upstream. Captured material is then withdrawn by using the PercuSurge Export aspiration catheter before the balloon of the GuardWire Plus is deflated and blood flow restored. The device has been used in over 5,000 procedures since its release in Europe during 1999 and was the first distal protection product to be commercialized there. The product's first targeted indication is for the treatment of degenerated saphenous vein grafts that show signs of disease following heart bypass surgery. The GuardWire Plus is an investigational device in the United States, and clinical trials are already underway. Edited by Ursula Jones
PercuSurge Frequently Asked Questions (FAQ)
Where is PercuSurge's headquarters?
PercuSurge's headquarters is located at Sunnyvale.
What is PercuSurge's latest funding round?
PercuSurge's latest funding round is Acquired.
How much did PercuSurge raise?
PercuSurge raised a total of $58.2M.
Who are the investors of PercuSurge?
Investors of PercuSurge include Medtronic, InterWest Partners, MedVenture Associates, BioVentures Investors, Montreux Equity Partners and 3 more.
Who are PercuSurge's competitors?
Competitors of PercuSurge include SetPoint Medical, PulmonX, Prometheus Laboratories, SmartPill Corporation, Micronics Microfluidics and 7 more.
Compare PercuSurge to Competitors
Medical devices for the treatment of severe gastrointestinal disorders
SetPoint Medical develops implantable bioelectronic therapies to treat chronic inflammatory diseases.. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. It was formerly known as Innovative Metabolics. The company was founded in 2007 and is based in Valencia, California.
Pavad develops medical devices for the treatment of sleep apnea.
MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.
Mobius Therapeutics is a company focused on perioperative pharmaceuticals within the ophthalmology sector. They offer a range of pharmaceutical products designed to improve patient care, access, and provider safety during the perioperative period of eye surgeries. The company primarily serves healthcare providers and patients in the field of ophthalmology. It is based in St. Louis, Missouri.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.